# C4 Therapeutics (CCCC) — Analyst Forecast

CCCC · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cccc/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 8 | 0 | 0 | 8 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 9, 2026 | JP Morgan | Initiated Coverage | Overweight | $10.00 |
| Jun 1, 2026 | Evercore ISI Group | Maintained | Outperform | $12.00 |
| Feb 27, 2026 | Barclays | Maintained | Overweight | $7.00 |
| Feb 23, 2026 | Brookline Capital | Maintained | Buy | $30.00 |
| Dec 17, 2025 | Barclays | Maintained | Overweight | $5.00 |
| Dec 2, 2025 | TD Cowen | Initiated Coverage | Buy | — |
| Sep 23, 2025 | Barclays | Maintained | Overweight | $10.00 |
| Sep 23, 2025 | Wells Fargo | Maintained | Overweight | $10.00 |
| Sep 22, 2025 | Stephens & Co. | Maintained | Overweight | $6.00 |
| Sep 17, 2025 | Barclays | Initiated Coverage | Overweight | $8.00 |
| Sep 15, 2025 | Stephens & Co. | Upgraded | Equal-Weight → Overweight | $6.00 |
| Sep 4, 2025 | Guggenheim | Initiated Coverage | Buy | $8.00 |
| Dec 19, 2024 | Wells Fargo | Upgraded | Equal-Weight → Overweight | $12.00 |
| Nov 18, 2024 | Stephens & Co. | Initiated Coverage | Equal-Weight | $4.00 |
| Aug 6, 2024 | BMO Capital | Maintained | Outperform | $20.00 |
| May 9, 2024 | Stifel | Maintained | Buy | $14.00 |
| May 9, 2024 | Wells Fargo | Maintained | Equal-Weight | $8.00 |
| Feb 26, 2024 | Morgan Stanley | Maintained | Equal-Weight | $8.00 |
| Feb 23, 2024 | Stifel | Maintained | Buy | $13.00 |
| Jan 29, 2024 | JP Morgan | Upgraded | Underweight → Neutral | $6.00 |

## Frequently Asked Questions

### Is CCCC a buy, sell, or hold?

Analysts covering C4 Therapeutics currently average a Buy rating: 8 buy, 0 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on CCCC?

On Oct 9, 2026, JP Morgan initiated coverage of C4 Therapeutics at Overweight with a price target of $10.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).